The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Miroshnichenko I.I.

Mental Health Research Center, Moscow

Iakovleva O.B.

Safarova T.P.

Shipilova E.S.

FGBU "Nauchnyĭ tsentr psikhicheskogo zdorov'ia" RAMN, Moskva

Baymeeva N.V.

Mental Health Research Center, Moscow

The content of N-acetylaspartate in depressed elderly patients during therapy with antidepressants and actovegin

Authors:

Miroshnichenko I.I., Iakovleva O.B., Safarova T.P., Shipilova E.S., Baymeeva N.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4): 38‑42

DOI: 10.17116/jnevro201911904138

Read: 1300 times

Download PDF (RU)
Contact the author
Table of contents

THE CONTENT OF N-ACETYLASPARTATE IN DEPRESSED ELDERLY PATIENTS DURING THERAPY WITH ANTIDEPRESSANTS AND ACTOVEGIN
THE CONTENT OF N-ACETYLASPARTATE IN DEPRESSED ELDERLY PATIENTS DURING THERAPY WITH ANTIDEPRESSANTS AND ACTOVEGIN

To cite this article:

Miroshnichenko II, Iakovleva OB, Safarova TP, Shipilova ES, Baymeeva NV. The content of N-acetylaspartate in depressed elderly patients during therapy with antidepressants and actovegin. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):38‑42. (In Russ.)
https://doi.org/10.17116/jnevro201911904138

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effect of poly­morphic variants of the HTR2A gene on the effe­ctiveness and safety of sertraline in patients with mixed anxiety-depressive diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):75-84
Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138
Asso­ciations of poly­morphic variants of CYP2C19*2, *17 with effe­ctiveness and safety of sertraline in adolescents with a depressive episode and suicidal tendencies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):12-20
Cogi­tum in the treatment of mental diso­rders in childhood. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):88-95
Transcranial electrostimulation as part of combination therapy for mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(1):37-44
Neuropathic pain in chro­nic inflammatory demye­linating poly­neuropathies: analysis of 64 cases. Russian Journal of Pain. 2025;(2):45-53
Psychodermatological aspe­cts of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):403-411
Effe­cts of corticosterone and anti­depressants fluoxetine and amitriptyline on the expression of neurotrophic factors in rat astrocytoma C6 cells. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(4-2):111-120
Abstract:

Objective. To assess the plasma level of N-acetylaspartate (NAA) before and after combined therapy with antidepressants and actovegin in a group of elderly patients diagnosed with depression. Material and methods. Nineteen patients, 7 men and 12 women, mean age 70.5±5.8 years, were studied using clinical examination and psychometric scales as well as computed tomography (CT). NAA plasma levels were determined. The duration of treatment with antidepressants (venlafaxine, fluvoxamine) and actovegin was 28 days, patients were examined at baseline and on the 28th day of treatment. Results and conclusion. The NAA plasma level was reduced in patients compared to healthy volunteers. The increase of this indicator after treatment reflected a significant improvement on clinical and psychometric measures. The dynamics of NAA changes (increase or decrease) showed heterogeneity in the group of patients, which was not related to the efficacy of treatment but was correlated with comorbid diseases, in particular vascular diseases, and CT changes (leukoaraiosis). The authors consider the results of this study as preliminary.

Keywords:

depression in older adults
antidepressants
actovegin
N-acetylaspartate

Authors:

Miroshnichenko I.I.

Mental Health Research Center, Moscow

Iakovleva O.B.

Safarova T.P.

Shipilova E.S.

FGBU "Nauchnyĭ tsentr psikhicheskogo zdorov'ia" RAMN, Moskva

Baymeeva N.V.

Mental Health Research Center, Moscow

Close metadata

References:

  1. Gavrilova SI, Kalyn YaB. Socio-environmental factors and the state of mental health of the elderly population (clinical epidemiological study). Vestnik RAMN. 2002;9:15-20. (In Russ.)
  2. Baldwin R, Wild R. Management of depression in later life. Advances in Psychiatric Treatment. 2004;10:131-139. https://doi.org/10.1192/apt.10.2.131
  3. Blazer D. Depression in late life: review and commentary. Journal of Gerontology. 2003;3:249-265. https://doi.org/10.1007/978-3-662-40455-3_6
  4. Kok RM, Reynolds CF. 3rd. Management of depression in older adults: A review. JAMA. 2017;20:2114-2122. https://doi.org/10.1001/jama.2017.5706
  5. Katona C, Livingston G. How well do antidepressants work in older people? A systematic review of number needed to treat. Journal of Affective Disorders. 2002;69:47-52. https://doi.org/10.1016/s0165-0327(00)00332-3
  6. Coffey CE, Figiel GS, Djang WT, Weiner RD. Subcortical hyperintensity on MRI: a comparison of normal and depressed elderly subjects. Am J Psychiatry. 1990;147:187-189. https://doi.org/10.1176/ajp.147.2.187
  7. Yakovleva OB. Pozdniye depressii i sosudistyye faktory riska. Psychiatry. 2004:7:25-31. (In Russ.)
  8. Alexopoulos GS. Frontostriatal and limbic dysfunction in late-life depression. Am J Geriatr Psychiatry. 2002;10:687-695. https://doi.org/10.1176/appi.ajgp.10.6.687
  9. Machicao F, Muresanu DF, Hundsberger H, Pflüger M, Guekh A. Pleiotropic neuroprotective and metabolic effects of Actovegin’s mode of action. Journal of the Neurological Sciences. 2012;322:222-227. https://doi.org/10.1016/j.jns.2012.07.069
  10. Søndergård SD, Dela F, Helge JW, Larsen S. Actovegin, a non-prohibited drug increases oxidative capacity in human skeletal muscle. Eur J Sport Sci. 2016;7:801-807. https://doi.org/10.1080/17461391.2015.1130750
  11. Korczyn AD, Brainin M, Guekht A. Neuroprotection in ischemic stroke: what does the future hold? Expert Rev Neurother. 2015;3:227-229. https://doi.org/10.1586/14737175.2015.1014806
  12. Baymeeva NV, Miroshnichenko II. N-acetylaspartate is a biomarker of psychiatric and neurological disorders. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115: 8:54-58. (In Russ.) https://doi.org/10.17116/jnevro20151158194-98
  13. Ruggieri M, Tortorella C, Ceci E. Age-related changes of serum N-acetylaspartate in healthy control. Research letters. J Age and Ageing. 2011;40(3):391-394. https://doi.org/10.1093/ageing/afr021
  14. Waragai M, Moriya M, Nojo T. Decreased N-Acetyl Aspartate/Myo-Inositol Ratio in the Posterior Cingulate Cortex Shown by Magnetic Resonance Spectroscopy May Be One of the Risk Markers of Preclinical Alzheimer’s Disease: A 7-Year Follow-Up Study. J Alzheimers Dis. 2017;4:1411-142. https://doi.org/10.3233/jad-170450
  15. Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Phillips L, Pantelis C. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: A magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra — high-risk individuals. Archives of General Psychiatry. 2006;2:139-149. https://doi.org/10.1001/archpsyc.63.2.139
  16. Mondino M, Brunelin J, Saoud M. N-acetyl-aspartate level is decreased in the prefrontal cortex in subjects at-risk for schizophrenia. Frontiers in Psychiatry. 2013;4:99.
  17. Aydin B, Yurt A, Gökmen N, Renshaw P, Olson D, Yildiz A. Trait-related alterations of N-acetylaspartate in euthymic bipolar patients: A longitudinal proton magnetic resonance spectroscopy study. J Affect Disord. 2016;206:315-320. https://doi.org/10.1016/j.jad.2016.09.002
  18. Zimmerman M, Martin J, Clark H, McGonigal P, Harris L, Holst CG. Measuring anxiety in depressed patients: A comparison of the Hamilton anxiety rating scale and the DSM-5 Anxious Distress Specifier Interview. J Psychiatr Res. 2017;93:59-63. https://doi.org/10.1016/j.jpsychires.2017.05.014
  19. Baymeeva NV. Quantitative determination of N-acetylaspartate in plasma by high-performance liquid chromatography with a mass detector. Psychiatry. 2014;3:25-25a. (In Russ.)
  20. Baymeeva NV, Platova AI, Safarova TP, Yakovleva OB, Sheshenin VS, Shipilova ES, Kornilov VV, Miroshnichenko II. Rol’ biomarkerov v diagnostike i terapii depressii. Digest Theses of XXIV Ross. Nat. Congress «Man and medicine». M. 2017;120. (In Russ.)
  21. Yakovleva OB, Fedorov VV, Ryakhovskiy VV. The costs of depressions in later life. Psychiatry. 2011;2:5-12. (In Russ.)
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.